Literature DB >> 32267551

Primary Advanced Squamous Cell Carcinoma of the Temporal Bone: A Single-Center Clinical Study.

Noritaka Komune1, Teppei Noda1, Ryunosuke Kogo1, Masaru Miyazaki2, Nana A Tsuchihashi1, Takahiro Hongo1, Kensuke Koike1, Kuniaki Sato1, Rhutaro Uchi1, Takahiro Wakasaki1, Nozomu Matsumoto1, Ryuji Yasumatsu1, Takashi Nakagawa1.   

Abstract

OBJECTIVES/HYPOTHESIS: The extreme rarity of temporal bone squamous cell carcinoma (TB-SCC) has delayed the accumulation of high-quality clinical evidence. For the purposes of retrospective meta-analysis in the future, a large dataset with information from various institutions would be ideal. Our objective here was to retrospectively review cases of TB-SCC encountered at a single tertiary referral center and explore survival outcomes and prognostic factors. STUDY
DESIGN: Retrospective chart review.
METHODS: The medical records of all TB-SCC cases were retrospectively reviewed. The resulting dataset contained 71 cases of primary cancer eligible for initial definitive (curative) treatment.
RESULTS: T4 status was associated with lower disease-specific 5-year survival than T1 to T3 staging (T1: 100%, T2: 92%, T3: 86%, T4: 51%). Survival was significantly higher in operable than in inoperable cases, even when restricted to advanced (T3/T4) cancers. The tumor extension to the middle ear cavity was observed in 13/17 of T3 cases, but it was not associated with poor survival. In addition, among operable cases, negative surgical margins were associated with significantly higher survival than positive margins.
CONCLUSIONS: Definitive treatments can offer disease-specific 5-year survival of over 85% in T1 to T3 cases of TB-SCC. The tumor extension to the middle ear cavity is not associated with poor survival. T4 status, inoperability, nodal invasion, and positive surgical margin are identified as a predictor of poor prognosis. Still, the matter of how to deal with unresectable tumors remains an outstanding issue in the treatment of TB-SCC. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E583-E589, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Squamous cell carcinoma; external auditory canal; temporal bone

Year:  2020        PMID: 32267551     DOI: 10.1002/lary.28653

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma.

Authors:  Ke Qiu; Wendu Pang; Jianqing Qiu; Junhong Li; Danni Cheng; Yufang Rao; Yijun Dong; Minzi Mao; Qiurui Liu; Xiaosong Mu; Wei Zhang; Wei Xu; Jianjun Ren; Yu Zhao
Journal:  Cancer Med       Date:  2021-09-24       Impact factor: 4.452

2.  Treatment of advanced squamous cell carcinoma of the external auditory canal: Critical analysis of persistent failures in diagnosis and surgery with a competing-risk model.

Authors:  Antonio Mazzoni; Diego Cazzador; Gino Marioni; Elisabetta Zanoletti
Journal:  Head Neck       Date:  2022-06-02       Impact factor: 3.821

3.  Evaluation of subclasses for T4-classified squamous cell carcinoma of the external auditory canal.

Authors:  Cindy H Nabuurs; Wietske Kievit; C René Leemans; Conrad F G M Smit; Michiel W M van den Brekel; Robert J Pauw; Bernard F A M van der Laan; Jeroen C Jansen; Martin Lacko; Weibel W Braunius; Chunfu Dai; Xunbei Shi; Giovanni Danesi; Jan Bouček; Robert P Takes; Henricus P M Kunst
Journal:  Head Neck       Date:  2022-05-13       Impact factor: 3.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.